pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

3,250 catalysts · 4,728 grant · 3,086 8k filing · 2,667 approval · 2,309 device 510k · 1,852 device recall · 1,612 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 57 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: earnings×type: approval×from 2025-07-21×clear all
type
  • grant4,728
  • 8k filing3,086
  • approval2,667
  • device 510k2,309
  • device recall1,852
  • device pma1,612
device adverse event
1,000
  • recall617
  • earnings583
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jul 21, 2025

    12
    ›Jul 21, 2025approval387d agoNEXLETOL (BEMPEDOIC ACID) — FDA approvalbempedoic acid

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →bempedoic acid →fda approvals ↗
    ›Jul 21, 2025approval387d agoNEXLETOL (BEMPEDOIC ACID) — FDA approvalbempedoic acid

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →bempedoic acid →fda approvals ↗
    ›Jul 21, 2025approval387d agoNEXLIZET (BEMPEDOIC ACID) — FDA approval(bempedoic acid + ezetimibe)

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →(bempedoic acid + ezetimibe) →fda approvals ↗
    ›Jul 21, 2025approval387d agoNEXLIZET (BEMPEDOIC ACID) — FDA approval(bempedoic acid + ezetimibe)

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →(bempedoic acid + ezetimibe) →fda approvals ↗
    ›Jul 21, 2025approval387d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jul 21, 2025approval387d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jul 22, 2025approval386d agoXYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE) — FDA approvalSanofi

    Sponsor: CHATTEM SANOFI. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Jul 23, 2025approval385d agoOTEZLA (APREMILAST) — FDA approvalapremilast

    Sponsor: AMGEN INC. Form: TABLET. Route: ORAL

    full page →apremilast →fda approvals ↗
    ›Jul 24, 2025approval384d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jul 24, 2025approval384d agoHALOPERIDOL DECANOATE — FDA approvalHALOPERIDOL DECANOATE

    Sponsor: MANKIND PHARMA. Form: INJECTABLE. Route: INJECTION

    full page →HALOPERIDOL DECANOATE →fda approvals ↗
    ›Jul 25, 2025approval383d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: ALEMBIC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jul 25, 2025approval383d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

    Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INTRAVENOUS

    full page →IBANDRONATE SODIUM →fda approvals ↗

    Week of Jul 28, 2025

    16
    ›Jul 28, 2025approval380d agoCOPIKTRA (DUVELISIB) — FDA approvalSecura Bio Inc

    Sponsor: SECURA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 29, 2025approval

    Week of Aug 4, 2025

    17
    ›Aug 4, 2025approval373d agoOXYCODONE HYDROCHLORIDE — FDA approvalOXYCODONE HYDROCHLORIDE

    Sponsor: ASCENT PHARMS INC. Form: TABLET. Route: ORAL

    full page →OXYCODONE HYDROCHLORIDE →fda approvals ↗
    ›Aug 5, 2025approval

    Week of Aug 11, 2025

    5
    ›Aug 11, 2025approval366d agoDEFLAZACORT — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: UPSHER SMITH LABS. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Aug 12, 2025approval
    ← prev
    page 1 of 65
    next →
    379d ago
    AVTOZMA (TOCILIZUMAB-ANOH) — FDA approvalAVTOZMA

    Sponsor: CELLTRION INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →AVTOZMA →fda approvals ↗
    ›Jul 29, 2025approval379d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PH HEALTH. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 29, 2025approval379d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PH HEALTH. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 29, 2025approval379d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›Jul 30, 2025approval378d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jul 30, 2025approval378d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jul 30, 2025approval378d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 30, 2025approval378d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 30, 2025approval378d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 31, 2025approval377d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›Jul 31, 2025approval377d agoLEQVIO (INCLISIRAN SODIUM) — FDA approvalinclisiran

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →inclisiran →fda approvals ↗
    ›Aug 1, 2025approval376d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval376d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval376d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval376d agoNURTEC ODT (RIMEGEPANT SULFATE) — FDA approvalrimegepant sulfate ODT

    Sponsor: PFIZER. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →rimegepant sulfate ODT →fda approvals ↗
    372d ago
    DAYBUE (TROFINETIDE) — FDA approvaltrofinetide

    Sponsor: ACADIA PHARMS INC. Form: SOLUTION. Route: ORAL

    full page →trofinetide →fda approvals ↗
    ›Aug 5, 2025approval372d agoDAYBUE (TROFINETIDE) — FDA approvaltrofinetide

    Sponsor: ACADIA PHARMS INC. Form: SOLUTION. Route: ORAL

    full page →trofinetide →fda approvals ↗
    ›Aug 5, 2025approval372d agoPOMALIDOMIDE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 5, 2025approval372d agoPOMALIDOMIDE — FDA approvalPOMALIDOMIDE

    Sponsor: MYLAN. Form: CAPSULE. Route: ORAL

    full page →POMALIDOMIDE →fda approvals ↗
    ›Aug 6, 2025approval371d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 6, 2025approval371d agoCOSENTYX (SECUKINUMAB) — FDA approvalNOVARTIS AG

    Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Aug 6, 2025approval371d agoLAMOTRIGINE — FDA approvalLAMOTRIGINE

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →LAMOTRIGINE →fda approvals ↗
    ›Aug 6, 2025approval371d agoLAMOTRIGINE — FDA approvalTorrent Pharma Inc

    Sponsor: UNICHEM LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 6, 2025approval371d agoIBANDRONATE SODIUM — FDA approvalDR REDDYS LABORATORIES LTD

    Sponsor: PHARMOBEDIENT. Form: INJECTABLE. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Aug 6, 2025approval371d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

    Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

    full page →ganaxolone →fda approvals ↗
    ›Aug 7, 2025approval370d agoPRUCALOPRIDE SUCCINATE — FDA approvalPRUCALOPRIDE SUCCINATE

    Sponsor: ZYDUS LIFESCIENCES. Form: TABLET. Route: ORAL

    full page →PRUCALOPRIDE SUCCINATE →fda approvals ↗
    ›Aug 8, 2025approval369d agoSODIUM ACETATE — FDA approvalSODIUM ACETATE

    Sponsor: AMNEAL. Form: SOLUTION. Route: INTRAVENOUS

    full page →SODIUM ACETATE →fda approvals ↗
    ›Aug 8, 2025approval369d agoHERNEXEOS (ZONGERTINIB) — FDA approvalzongertinib

    Sponsor: BOEHRINGER INGELHEIM. Form: TABLET. Route: ORAL

    full page →zongertinib →fda approvals ↗
    ›Aug 8, 2025approval369d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

    full page →tocilizumab →fda approvals ↗
    ›Aug 8, 2025approval369d agoACTEMRA (TOCILIZUMAB) — FDA approvaltocilizumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INTRAVENOUS, SUBCUTANEOUS

    full page →tocilizumab →fda approvals ↗
    ›Aug 8, 2025approval369d agoIRON SUCROSE — FDA approvalsuccharated ferric oxide

    Sponsor: SANDOZ. Form: INJECTABLE. Route: INTRAVENOUS

    full page →succharated ferric oxide →fda approvals ↗
    365d ago
    RINVOQ (UPADACITINIB) — FDA approvalupadacitinib tartrate ER

    Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →upadacitinib tartrate ER →fda approvals ↗
    ›Aug 14, 2025approval363d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval363d agoOTULFI (USTEKINUMAB-AAUZ) — FDA approvalOTULFI

    Sponsor: FRESENIUS KABI USA. Form: INJECTABLE. Route: INJECTION

    full page →OTULFI →fda approvals ↗
    ›Aug 14, 2025approval363d agoLAZCLUZE (LAZERTINIB MESYLATE) — FDA approvallazertinib mesylate

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →lazertinib mesylate →fda approvals ↗
    $SNY43.48+0.05%
    $ESPR
    $ESPR
    $ESPR
    $ESPR
    $IGC0.2670+0.41%
    $AMRX17.47-2.29%
    $NVS155.21-1.01%
    $PFE26.63-1.57%
    $ACAD29.39+0.62%
    $AMGN417.20+1.52%
    $IGC0.2670+0.41%
    $ACAD29.39+0.62%
    $NVS155.21-1.01%
    $RDY12.15-0.57%
    $NVS155.21-1.01%
    $AMRX17.47-2.29%
    $ABBV247.97+0.78%